Medicare Coverage of Aducanumab — Implications for State Budgets

Abstract

CMS is considering whether and under what circumstances Medicare will pay for aducanumab for Alzheimer’s disease. A restrictive coverage determination could save the federal government money, but it would also shift substantial costs to states.